BioCryst Plans to Raise $100 Million

BioCryst Plans to Raise $100 Million

Source: 
Motley Fool
snippet: 

On the cusp of launching berotralstat as a treatment for hereditary angioedema in the U.S. and EU, BioCryst Pharmaceuticals (NASDAQ:BCRX) is planning to sell $100 million of stock in a secondary offering. The underwriters will have a 30-day option to purchase another $15 million, so the biotech could potentially gross $115 million in the offering.